Erdheim–Chester Disease With Multiorgan Involvement, Following Polycythemia Vera

Abstract Erdheim–Chester disease is a rare form of non-Langerhans cell histiocytosis characterized by the migration and infiltration of lipid-laden CD68+, CD1a− and S100− histiocytes to various target organs, which leads to the disruption of physiological tissue architecture and reactive fibrosis, and thus impairs organ function. We describe the first case of a patient with Erdheim–Chester disease with multiorgan involvement developed after 6 years from polycythemia vera diagnosis. During the follow-up, an abdominal ultrasound scan revealed the presence of dense, bilateral perinephric infiltration. A computed tomographic guided core biopsy was performed in order to identify the histological nature of this lesion, and a morphological analysis demonstrated the accumulation of foamy histiocytes surrounded by fibrosis. The BRAFV600E mutation was detected, and a diagnosis of Erdheim–Chester disease was made. The extreme rarity of Erdheim–Chester disease strongly suggests the existence of potentially common element(s) that may have contributed to the pathogenesis of both disorders. Obviously, further studies are needed to clarify the mutual roles and effects of JAK2 and BRAF mutations in this patient, as well as their possible therapeutic implications.

[1]  S. Verstovsek,et al.  Polycythemia vera and essential thrombocythemia , 2018 .

[2]  J. Snowden,et al.  The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.

[3]  A. Tomelleri,et al.  Erdheim-Chester disease. , 2015, European journal of internal medicine.

[4]  M. Ferrarini,et al.  Cardiovascular manifestations of Erdheim-Chester disease. , 2015, Clinical and experimental rheumatology.

[5]  P. Grenier,et al.  Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Barbui,et al.  CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management , 2015 .

[7]  M. Griesshammer,et al.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.

[8]  O. Abdel-Wahab,et al.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. , 2014, Blood.

[9]  K. Chang,et al.  Erdheim-Chester disease with rare radiological features in a 14-year old girl with pre-B Acute Lymphocytic Leukemia and Diabetes Mellitus. , 2014, Journal of radiology case reports.

[10]  O. Abdel-Wahab,et al.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. , 2014, Blood.

[11]  G. Cavalli,et al.  Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim–Chester Disease , 2014, Front. Immunol..

[12]  M. Cazzola,et al.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.

[13]  P. Cluzel,et al.  Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. , 2013, Blood.

[14]  C. Campochiaro,et al.  The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases , 2013, Annals of the rheumatic diseases.

[15]  M. Copin,et al.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. , 2012, Blood.

[16]  R. Hoffman,et al.  The renaissance of interferon therapy for the treatment of myeloid malignancies. , 2011, Blood.

[17]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[19]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[20]  A. Salar,et al.  Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients , 2009, British journal of haematology.

[21]  M. Ferrarini,et al.  Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. , 2006, Arthritis and rheumatism.

[22]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[23]  F. Sim,et al.  Erdheim-Chester disease. , 2003, Orthopedics.

[24]  C. Clerici,et al.  Polycythemia vera treated with recombinant interferon‐alpha 2a: Evidence of a selective effect on the malignant clone , 1997, American journal of hematology.

[25]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.